Form 4: MAIA Biotechnology Director Steven M. Chaouki Reports Stock Option Grant
SEC Form 4 Filing
Director Steven M. Chaouki reports acquisition of stock options in MAIA Biotechnology, Inc.
Summary
- On October 1, 2024, Steven M. Chaouki, a director of MAIA Biotechnology, Inc., filed a Form 4.
- The report details the grant of stock options to Chaouki on September 30, 2024.
- Chaouki acquired 7,232 stock options with an exercise price of $2.81.
- These options vest immediately and are exercisable from the grant date, expiring on September 30, 2034.
- Following the transaction, Chaouki directly owns 7,232 derivative securities.
Sentiment
Score: 6
Explanation: The sentiment is neutral as it reports a standard stock option grant, which is neither particularly positive nor negative.
Positives
- The grant of stock options aligns the director's interests with those of the shareholders.
- Immediate vesting of the options could incentivize the director to contribute to the company's success promptly.
Industry Context
Stock option grants are a common practice in the biotechnology industry to incentivize executives and align their interests with shareholders.
Stakeholder Impact
- The stock option grant could potentially impact shareholders by diluting equity if the options are exercised.
Key Dates
| Date | Description |
|---|---|
| 09/30/2024 | Date of stock options grant |
| 09/30/2024 | Stock options vest 100% and are exercisable |
| 09/30/2034 | Expiration date of the stock options |
| 10/01/2024 | Date of Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.